HK1250731A1 - 用於治療癌症的免疫原性融合蛋白 - Google Patents

用於治療癌症的免疫原性融合蛋白

Info

Publication number
HK1250731A1
HK1250731A1 HK18110072.0A HK18110072A HK1250731A1 HK 1250731 A1 HK1250731 A1 HK 1250731A1 HK 18110072 A HK18110072 A HK 18110072A HK 1250731 A1 HK1250731 A1 HK 1250731A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
fusion proteins
immunogenic fusion
immunogenic
Prior art date
Application number
HK18110072.0A
Other languages
English (en)
Inventor
D‧G‧布羅克施泰特
P‧M‧勞爾
W‧G‧漢森
M‧L‧L‧里昂
M‧法索
C‧S‧雷
C‧G‧德雷克
Original Assignee
艾杜羅生物科技公司
約翰霍普金斯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾杜羅生物科技公司, 約翰霍普金斯大學 filed Critical 艾杜羅生物科技公司
Publication of HK1250731A1 publication Critical patent/HK1250731A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18110072.0A 2015-04-13 2018-08-06 用於治療癌症的免疫原性融合蛋白 HK1250731A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562146654P 2015-04-13 2015-04-13
US201562146626P 2015-04-13 2015-04-13
US201562263174P 2015-12-04 2015-12-04
PCT/US2016/027167 WO2016168214A2 (en) 2015-04-13 2016-04-12 Immunogenic fusion proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1250731A1 true HK1250731A1 (zh) 2019-01-11

Family

ID=55808893

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110072.0A HK1250731A1 (zh) 2015-04-13 2018-08-06 用於治療癌症的免疫原性融合蛋白
HK18110240.7A HK1250662A1 (zh) 2015-04-13 2018-08-09 用於治療癌症的免疫原性融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110240.7A HK1250662A1 (zh) 2015-04-13 2018-08-09 用於治療癌症的免疫原性融合蛋白

Country Status (11)

Country Link
US (2) US9808516B2 (zh)
EP (1) EP3283100A2 (zh)
JP (1) JP2018512165A (zh)
CN (1) CN107980044A (zh)
AU (1) AU2016247894A1 (zh)
CA (1) CA2982543A1 (zh)
HK (2) HK1250731A1 (zh)
MA (1) MA44378A (zh)
TW (1) TW201704267A (zh)
UY (1) UY36617A (zh)
WO (1) WO2016168214A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3495355A1 (en) 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
EP0796277B1 (en) 1994-11-28 2004-03-24 Thomas Jefferson University Fusion junction type iii mutant egf receptor peptide tumour vaccine
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4545151B2 (ja) 2003-02-06 2010-09-15 シーラス コーポレイション 非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
ATE546153T1 (de) 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
EP1991263B8 (en) 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
DK2640842T3 (en) 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
MX350795B (es) * 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
MX2015008329A (es) * 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
CN104211814A (zh) 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer

Also Published As

Publication number Publication date
MA44378A (fr) 2019-01-23
UY36617A (es) 2016-10-31
EP3283100A2 (en) 2018-02-21
AU2016247894A1 (en) 2017-10-26
CN107980044A (zh) 2018-05-01
WO2016168214A3 (en) 2016-12-22
US20180085446A1 (en) 2018-03-29
JP2018512165A (ja) 2018-05-17
US9808516B2 (en) 2017-11-07
CA2982543A1 (en) 2016-10-20
HK1250662A1 (zh) 2019-01-11
WO2016168214A2 (en) 2016-10-20
TW201704267A (zh) 2017-02-01
US20160324945A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL259996A (en) Combinations for cancer treatment
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
HUE055433T2 (hu) Kombinált készítmény rák kezelésére
HUE053654T2 (hu) FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
HK1250662A1 (zh) 用於治療癌症的免疫原性融合蛋白
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
ZA201902689B (en) Therapeutic protein
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
EP3139955A4 (en) Fusion proteins for treating cancer and related methods
IL277377B (en) Prohemostatic proteins for the treatment of bleeding
IL265751B (en) Immunogenic compounds for cancer treatment
IL263564B (en) Peptides for the treatment of osteoarthritis
IL249610A (en) Chimeric proteins for cancer treatment
ZA201608886B (en) Human cytolytic fusion proteins
EP3261673B8 (en) Combined vaccination/radioterapy for cancer treatment
GB201616715D0 (en) Therapeutic protein
AU2015904120A0 (en) Selection methods for the treatment of cancer